MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis today announced the appointment of Adam Lowe as Vice President of Marketing. Mr. Lowe’s extensive experience building commercial and scientific teams in the genomics field will be critical in driving the company’s product and commercialization strategies.
Mr. Lowe brings over 20 years of life science experience in marketing, product development, business development, and research. Prior to joining Personalis, Adam served as Vice President of Commercial Operations at Oxford Nanopore Technologies. Mr. Lowe spent the previous five years at Illumina, where he built and led Illumina's product marketing/management team for next-generation sequencing. Mr. Lowe served as Director of Scientific Operations at Applied Biosystems (now Life Technologies), worked in business development at Agilent Technologies, co-founded a small biotechnology consulting firm, and was the first employee of Genetic Health, a healthcare startup focused on building on-line tools for risk assessment, management, and research on the genetic basis of common disease.
“I had the pleasure of working with Adam previously at Illumina and Applied Biosystems, and am very pleased to have someone of his experience, energy, and vision join our team,” said Personalis CEO John West. “His knowledge of genomics and next-generation sequencing, combined with his ability to build a talented marketing team, will be critical as we expand our portfolio and commercial reach.”
“I’m extremely excited to join Personalis,” said Mr. Lowe. “Having seen both the promise as well as the existing gaps in applying NGS to understanding disease, it is clear to me that the Personalis team is miles ahead of anyone else in bringing this technology to broad application in human health.”
In this new position, Mr. Lowe will recruit and lead Personalis’ marketing organization and serve as a key member of the company’s management team.
Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology™ supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy. (www.personalis.com)